Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Moser, G. J.
Right arrow Articles by Goldsworthy, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moser, G. J.
Right arrow Articles by Goldsworthy, T. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal Article

Quantitative Relationship Between Transforming Growth Factor-Alpha and Hepatic Focal Phenotype and Progression in Female Mouse Liver

Glenda J. Moser

Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina 27709

Douglas C. Wolf

Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina 27709

Thomas L. Goldsworthy

Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina 27709

Modulations in the positive hepatocyte growth factor, transforming growth factor-alpha (TGF-{alpha}) and its receptor epidermal growth factor receptor (EGFR), occur in rat and human liver tumors. The purpose of this study was to determine if TGF-{alpha} and EGFR are altered in basophilic and acidophilic preneoplastic and neoplastic liver lesions generated in DEN-initiated mice exposed to a variety of hepatocarcinogens. Female B6C3F1 mice were initiated with N-nitrosodiethylamine (DEN) and treated with hepatocarcinogenic concentrations of unleaded gasoline vapor (2,000 ppm), methyl tertiary butyl ether vapor (7,814 ppm), phenobarbital (500 ppm, diet), or chlordane (25 ppm, diet). Hepatic foci and tumors were identified and evaluated immunohistochemically with antibodies for TGF-{alpha} and EGFR. In all treatment groups, basophilic hepatic foci were negative for TGF-{alpha} immunoreactivity (554/564, 98%). In contrast, regardless of treatment, acidophilic hepatic foci were immunoreactive for TGF-{alpha} (107/108, 99%). There was no significant difference in mean hepatic labeling index as measured by the incorporation of 5-bromo-2'-deoxyuridine between foci immunoreactive and nonimmunoreactive for TGF-{alpha}. The incidence of immunoreactivity for TGF-{alpha} increased in hepatocellular tumors that were predominantly of the basophilic phenotype. Of basophilic hepatocellular adenomas, 16/81 (20%) were immunoreactive for TGF-{alpha}, while 17/29 (59%) of hepatocellular carcinomas stained positive for TGF-{alpha}. A similar increased incidence of EGFR immunoreactivity was found in basophilic hepatocellular adenomas (17/67, 25%) and carcinomas (19/28, 68%) relative to basophilic foci (11/367, 3%), suggesting an autocrine mechanism for the development of mouse liver tumors. The increased incidence of TGF-{alpha} immunoreactivity in basophilic liver tumors suggests that TGF-{alpha} is a marker of tumor progression in mouse liver. Furthermore, TGF-{alpha} modulations were dependent on phenotype rather than treatment, indicating inherent differences in the expression of TGF-{alpha} in basophilic and acidophilic hepatic lesions.

Key Words: Labeling indices • tumor promotion • N-nitrosodiethylamine (DEN) • phenobarbital • unleaded gasoline • methyl tertiary butyl ether (MTBE) • chlordane

Toxicologic Pathology, Vol. 25, No. 3, 275-283 (1997)
DOI: 10.1177/019262339702500305


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Toxicol PatholHome page
T. L. Goldsworthy and R. Fransson-Steen
Quantitation of the Cancer Process in C57BL/6J, B6C3F1 and C3H/HeJ Mice
Toxicol Pathol, January 1, 2002; 30(1): 97 - 105.
[Abstract] [PDF]


Home page
Toxicol PatholHome page
G.-H. Lee
Review Article: Paradoxical Effects of Phenobarbital on Mouse Hepatocarcinogenesis
Toxicol Pathol, March 1, 2000; 28(2): 215 - 225.
[Abstract] [PDF]


Home page
CarcinogenesisHome page
J. G. Christensen, E. H. Romach, L. N. Healy, A. J. Gonzales, S. P. Anderson, D. E. Malarkey, J. C. Corton, T. R. Fox, R. C. Cattley, and T. L. Goldsworthy
Altered bcl-2 family expression during non-genotoxic hepatocarcinogenesis in mice
Carcinogenesis, August 1, 1999; 20(8): 1583 - 1590.
[Abstract] [Full Text] [PDF]